These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1020607)

  • 1. Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes.
    Pontiroli AE; Viberti G; Pozza G
    Acta Diabetol Lat; 1976; 13(3-4):107-10. PubMed ID: 1020607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
    Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
    Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus.
    Ferrari C; Romussi M; Bertazzoni A; Testori GP; Grimaldi MG
    Biomedicine; 1978 Jun; 29(4):133-6. PubMed ID: 556385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of clofibrate on glucose tolerance in maturity onset diabetes.
    Barnett D; Craig JG; Robinson DS; Rogers MP
    Br J Clin Pharmacol; 1977 Aug; 4(4):455-8. PubMed ID: 901737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clofibrate on arginine-stimulated glucagon and insulin secretion in man.
    Eaton RP; Schade DS
    Metabolism; 1974 May; 23(5):445-54. PubMed ID: 4825301
    [No Abstract]   [Full Text] [Related]  

  • 6. [The influence of clofibrate on glucose metabolism in diabetes mellitus without endogenous hypertriglyceridemia (author's transl)].
    Vogelberg KH; Scherff R; Schulze-Schleppinghoff B
    Arzneimittelforschung; 1982; 32(4):413-6. PubMed ID: 7049189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
    Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
    Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
    Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
    Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased glucose disappearance rate after short-term clofibrate administration in normal subjects and in patients with chemical diabetes.
    Ferrari C; Testori GP; Bertazzoni A; Romussi M; Caldara R; Frezzati S
    Horm Metab Res; 1978 Jan; 10(1):4-6. PubMed ID: 631736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clofibrate on arginine-induced insulin and glucagon secretion.
    Eaton RP
    Metabolism; 1973 Jun; 22(6):763-7. PubMed ID: 4350845
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
    Schwandt P; Weisweiler P; Neureuther G; Wilkening J
    MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.
    Kobayashi M; Shigeta Y; Hirata Y; Omori Y; Sakamoto N; Nambu S; Baba S
    Diabetes Care; 1988 Jun; 11(6):495-9. PubMed ID: 3042317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 14. The diabetogenic action of somatostatin in healthy subjects and in maturity onset diabetics.
    Waldhäusl W; Bratusch-Marrain P; Dudczak R; Deutsch E
    J Clin Endocrinol Metab; 1977 May; 44(5):876-83. PubMed ID: 870515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance.
    Ebert R; Frerichs H; Creutzfeldt W
    Eur J Clin Invest; 1979 Apr; 9(2 Pt 1):129-35. PubMed ID: 111943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects.
    Matsumoto K; Miyake S; Yano M; Ueki Y; Yamaguchi Y; Akazawa S; Tominaga Y
    Diabetes Care; 1997 Oct; 20(10):1562-8. PubMed ID: 9314636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of clofibrate on carbohydrate metabolism in diabetics].
    Carapezzi C; Palummeri E; Soncini G; Bastoni L; Passeri M
    G Clin Med; 1976; 57(3-4):113-25. PubMed ID: 1001854
    [No Abstract]   [Full Text] [Related]  

  • 18. Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic alpha cells.
    Hamaguchi T; Fukushima H; Uehara M; Wada S; Shirotani T; Kishikawa H; Ichinose K; Yamaguchi K; Shichiri M
    Diabetologia; 1991 Nov; 34(11):801-6. PubMed ID: 1769438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.
    Murakami K; Nambu S; Koh H; Kobayashi M; Shigeta Y
    Br J Clin Pharmacol; 1984 Jan; 17(1):89-91. PubMed ID: 6362704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.